Bio-Path Holdings is a biotechnology company focused on the development of innovative cancer therapies that utilize its proprietary DNA-based drug delivery platform
The company’s main objective is to create and advance treatments that enhance the effectiveness of existing cancer treatments while reducing side effects. By leveraging its proprietary technology, Bio-Path aims to deliver therapeutic agents directly to cancer cells, thereby improving treatment outcomes and addressing unmet medical needs in oncology. The company is committed to advancing its drug candidates through clinical trials and collaboration with research institutions to bring new hope to patients battling cancer.
Bio-Path Holdings, Inc. (NASDAQBPTH) shares are surging Thursday following the company's announcement of encouraging preclinical results for BP1001-A, a potential treatment for obesity and Type 2 diabetes. Here's what you need to know.
Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set for Q4 2024.
Bio-Path Holdings shares are trading higher Friday after the company announced interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia.
